DewCell Inc. is Korea’s first and only company dedicated to developing artificial platelets, founded by experts in blood product R&D and clinical research planning. Leveraging iPSC (induced pluripotent stem cell) technology, DewCell aims to commercialize next-generation platelets that transcend blood type and ethnic limitations. Through its proprietary platform “en-aPLT,” the company is building pipelines for transfusion, therapeutic use, and cell culture media additives, while preparing to establish the world’s first large-scale production system with a 50L bioreactor. DewCell aspires to address the global blood shortage crisis and position itself as a leader in the field of advanced regenerative medicine.
